A SECRET WEAPON FOR DEUCRAVACITINIB

There have been no clinically substantial differences from the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when applied concomitantly with finerenone. Several doses of forty mg finerenone when-every day had no clinically applicable effect on AUC or Cmax with the BCRP and OATP substrate rosuvastatin.This